OSLO, NORWAY - March 12: Genetic Analysis AS ("GA" or "the Company") today announces the launch of GA-map® Dysbiosis Test AInsight ("AInsight"), an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice.
The GA-map® Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. While microbiome analysis provides valuable information on bacterial imbalance, interpreting complex microbial profiles remains a challenge for routine clinical practice.
AInsight supports healthcare professionals by structuring microbiome findings and contextualizing deviations in bacterial abundance using curated scientific evidence. The platform utilizes an AI language model to retrieve clinically relevant associations linked to each bacterial marker measured by the GA-map® Dysbiosis Test. By simplifying the interpretation of microbiome results, AInsight is expected to support the broader clinical use of the GA-map® Dysbiosis Test and contribute to increased demand for GA's reagent kit products.
Similar to the GA-map® Dysbiosis Test, which operates within a predefined and clinically validated closed diagnostic system, the AI model deployed in AInsight is restricted to retrieving information exclusively from GA's Bacteria Compendium - GA's curated knowledge base.
This controlled framework ensures that generated interpretation reports remain aligned with the validated scientific foundation underpinning the GA-map® Dysbiosis Test. The addition of AInsight enables automated generation of structured interpretation reports for individual microbiome profiles and supports scalable report generation for laboratory workflows, enabling laboratories to efficiently handle increasing testing volumes.
CEO Ronny Hermansen comments:
"We are pleased to introduce GA-map® Dysbiosis Test AInsight as part of our efforts to make clinically validated microbiome diagnostics easier to implement in routine healthcare. By simplifying interpretation of microbiome data, we aim to support broader adoption of the GA-map® Dysbiosis Test and enable laboratories to scale testing more efficiently."
The reports generated by GA-map® Dysbiosis Test AInsight are intended to provide informational support and should always be interpreted within the broader clinical context by qualified healthcare professionals. By lowering the barrier to interpreting microbiome test results, AInsight represents an important step in GA's strategy to expand the clinical use of its GA-map® diagnostic platform.
More information on AInsight: https://www.youtube.com/watch?v=qsMKXBSZ2Ag&feature=youtu.be&themeRefresh=1